A detailed history of Adar1 Capital Management, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 10,097 shares of PCVX stock, worth $876,722. This represents 0.19% of its overall portfolio holdings.

Number of Shares
10,097
Previous 12,250 17.58%
Holding current value
$876,722
Previous $925 Million 24.73%
% of portfolio
0.19%
Previous 0.17%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $151,829 - $252,159
-2,153 Reduced 17.58%
10,097 $1.15 Billion
Q2 2024

Aug 13, 2024

BUY
$60.06 - $78.77 $615,615 - $807,392
10,250 Added 512.5%
12,250 $925 Million
Q1 2024

May 15, 2024

BUY
$59.79 - $81.05 $113,601 - $153,995
1,900 Added 1900.0%
2,000 $137 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $4,535 - $6,341
100 New
100 $6.28 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.15B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.